grant

Predictive models for incident cirrhosis in non-alcoholic fatty liver disease using genetic and electronic medical record-based risk factors

Organization UNIVERSITY OF MICHIGAN AT ANN ARBORLocation ANN ARBOR, UNITED STATESPosted 1 Jul 2022Deadline 31 Mar 2027
NIHUS FederalResearch GrantFY2025Active Follow-upAddressAffectAgeAllelesAllelomorphsAmericanApplied GeneticsAwardBiopsyCalibrationCessation of lifeCirrhosisClinicalClinical geneticsComplexComputerized Medical RecordDataData SetDeathDisease ProgressionDrug TherapyElectronic Medical RecordEventFatty LiverFibrosisGWA studyGWASGene variantGene x Environment InteractionGeneticGenetic predisposing factorGoalsGrantGxE interactionHepatic CirrhosisHepatic DisorderHeritabilityHeterogeneityImpairmentInterventionInvestigatorsKnowledgeLaboratoriesLinkLiteratureLiverLiver CirrhosisLiver FibrosisLiver SteatosisLiver diseasesLogistic RegressionsMachine LearningMedicalMedical GeneticsMedicineMetabolicMichiganModelingNAFLDNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesParticipantPatient CarePatient Care DeliveryPatientsPersonsPharmacological TreatmentPharmacotherapyPhenotypePopulationPrecision HealthPredicting RiskProcessProviderQuality ControlResearchResearch PersonnelResearchersResource AllocationRiskRisk FactorsSourceStructureSubgroupTherapeutic InterventionTimeTrainingUnited StatesVariantVariationWritingactive followupagesallelic variantbasebasesbiobankbiorepositorycare for patientscare of patientscareercaring for patientscirrhoticclinical practiceco-morbidco-morbiditycohortcomorbiditycomputer based predictioncostdeath riskdemographicsdisease diagnosisdisease modeldisorder modeldrug interventiondrug treatmentelastic imagingelasticity imagingelastographyenvironment effect on genefibrotic liverfollow upfollow-upfollowed upfollowupforecasting riskgene environment interactiongenetic predictorsgenetic risk factorgenetic variantgenome wide associationgenome wide association scangenome wide association studygenomewide association scangenomewide association studygenomic varianthepatic body systemhepatic diseasehepatic fibrosishepatic organ systemhepatic steatosishepatopathyhepatosteatosishigh dimensional datahigh riskimprovedindexinginherited factorinterestintervention therapylife style interventionlifestyle interventionliver disordermachine based learningmachine learned algorithmmachine learning algorithmmachine learning based algorithmmachine learning based modelmachine learning based prediction modelmachine learning based predictive modelmachine learning modelmachine learning predictionmachine learning prediction modelmortality riskmultidimensional datamultidimensional datasetsnon-alcohol fatty liver diseasenon-alcoholic fatty liver diseasenon-alcoholic liver diseasenonalcoholic fatty liver diseasenoveloutcome predictionpharmaceutical interventionpharmacological interventionpharmacological therapypharmacology interventionpharmacology treatmentpharmacotherapeuticspolygenetic risk scorespolygenic risk scorepredict riskpredict riskspredicted riskpredicted riskspredicting riskspredictive modelingpredictive riskpredicts riskprogression riskprospectiverisk predictionrisk predictionsrisk stratificationstratify risksubstance usesubstance usingweight loss programweight loss programmingwhole genome association analysiswhole genome association study
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

Project Summary/Abstract
Non-alcoholic fatty liver disease (NAFLD) affects >80 million people in the United States and is implicated in

up 36% of liver-related deaths. While NAFLD is the fastest-growing cause of cirrhosis and liver-related

complications, not all patients with NAFLD ultimately develop cirrhosis. Our ability to identify which patients

are at highest risk is limited, which makes it challenging to allocate intensive lifestyle intervention and

pharmacologic therapy to those at highest risk. The strongest predictor of incident cirrhosis is fibrosis stage,

but existing fibrosis only identifies patients who have already progressed toward cirrhosis and requires

advanced phenotyping such as biopsy or transient elastography which are not universally available. It will be

critical to develop improved models for disease progression. This project focuses on two factors which may

improve risk stratification of progression to cirrhosis: genetics and machine learning using electronic medical

record (EMR) data. Heritability of liver fibrosis and cirrhosis is as high as 50%, and a number of genetic

variants have been linked to risk of cirrhosis. The EMR is a rich but complex source of data used in clinical

practice. When constructing models with such high-dimensional data, non-linear effects and interactions

between predictors are common; machine learning algorithms may outperform the more commonly-used

logistic regression models in this respect. The overall goal of this project is to generate predictive models for

which patients with NAFLD are most likely to progress to cirrhosis by integrating genetics and EMR-based

predictors with machine learning. The specific aims are (1) characterizing the effect of genetic risk factors on

rate of progression from NAFLD to cirrhosis, (2) training and validating machine learning models for incident

cirrhosis based on EMR data, and (3) generating integrated models incorporating both EMR and genetic data.

To accomplish these aims, Dr. Chen will obtain further training in processing of EMR data, the fundamentals

of statistical genetics, and machine learning and predictive modeling. Dr. Chen’s long-term goal is to become a

leading, independent investigator generating models to predict outcomes in NAFLD and eventually even

prioritize patients for treatment accordingly. An NIDDK K08 award will provide Dr. Chen with the necessary

time and training to achieve his career goals and improve care for patients with NAFLD. Overall, this project

will improve ability to predict which patients with NAFLD are most likely to develop cirrhosis and therefore

enhance precision health by helping medical providers prioritize persons at highest risk to more intensive

intervention.

Grant Number: 5K08DK132312-04
NIH Institute/Center: NIH

Principal Investigator: Vincent Chen

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →